Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase II Trial of PRT-064040 Nasal Spray for the Acute Treatment of Migraine

NCT07304518 Phase 2 RECRUITING

The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.

Details

Lead sponsor	Sichuan Purity Pharmaceutical Technology Co., Ltd.
Phase	Phase 2
Status	RECRUITING
Enrolment	456
Start date	2026-01-26
Completion	2026-10

Conditions

• Migraine

Interventions

• PRT-064040 nasal spray
• Placebo

Primary outcomes

• Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 2 hours post-dose
• Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose — 2 hours post-dose

Countries

China